EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial

Zhiqiang Song, Baojun Suo, Xueli Tian, Xinlu Ren, Yan Xue, Zhanyue Niu, Liya Zhou

Digestive and Liver Disease · 2023

DOI: 10.1016/j.dld.2022.12.019 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Digestive and Liver Disease, 2023. Verfasst von Zhiqiang Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking University Third Hospital, Beijing, 100191, China. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Quinolones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Peking University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: There are no randomized controlled trials that demonstrate the role of tailored therapy based on past medication history in improving efficacy of H. pylori eradication compared to empiric therapies. The objective of this study was to determine whether tailored triple plus bismuth therapy (TBT) can achieve higher eradication rates based on previous antibiotic history than empiric TBTs. METHODS: 800 treatment-naïve patients were randomly assigned to four groups receiving clarithromycin-, levofloxacin- or metronidazole-containing empiric TBT and tailored TBT (clarithromycin and levofloxacin chosen based on previous macrolides and quinolones medication history). Correlation analyses were performed between past medication history and resistance or eradication rate. RESULTS: The eradication rates of tailored TBT were significantly higher than clarithromycin-, levofloxacin- and metronidazole-containing empiric TBT in both intention-to-treat (89.5%, 80.8%, 81.5% and 81.5%) and per-protocol (95.1%, 86.7%, 86.5% and 87.8%) analyses (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter pyloriHelicobacter InfectionsQuinolonesHumansAnti-Bacterial AgentsBismuthClarithromycinMetronidazoleLevofloxacinProton Pump InhibitorsTreatment OutcomeDrug Therapy, CombinationMacrolidesAmoxicillin

Stichwörter der Autor:innen

Eradication rateHelicobacter pyloriPrevious antibiotic medication historyTailored therapyTriple plus bismuth therapy

Substanzen

Anti-Bacterial AgentsBismuthClarithromycinMetronidazoleLevofloxacinProton Pump InhibitorsMacrolidesQuinolonesAmoxicillin

Autor:innen und Institutionen

  • Department of Gastroenterology, Peking University Third Hospital, Beijing, 100191, China.
  • Department of Gastroenterology, Peking University Third Hospital, Beijing, 100191, China. Electronic address: zhouliya123456@163.com.

Förderung

  • Peking University
  • National Natural Science Foundation of China

Zitieren

APA

Song, Z., Suo, B., Tian, X., Ren, X., Xue, Y., Niu, Z., & Zhou, L. (2023). Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2022.12.019

Vancouver

Song Z, Suo B, Tian X, Ren X, Xue Y, Niu Z, et al. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial. Digestive and Liver Disease. 2023. doi:10.1016/j.dld.2022.12.019

BibTeX
@article{Song2023,
  author = {Song, Zhiqiang and Suo, Baojun and Tian, Xueli and Ren, Xinlu and Xue, Yan and Niu, Zhanyue and Zhou, Liya},
  title = {Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial},
  journal = {Digestive and Liver Disease},
  year = {2023},
  doi = {10.1016/j.dld.2022.12.019}
}
Kostenlos starten →